Targeted Protein Degradation Offers New Therapeutic Strategies for Blood Cancers

This article discusses the emerging therapeutic approach of targeted protein degradation in treating hematologic malignancies such as leukemia, lymphoma, and multiple myeloma. It highlights the limitations of current therapies and explains how methods like PROTACs and molecular glue degraders utilize the ubiquitin–proteasome system to selectively degrade pathogenic proteins, potentially overcoming resistance in tumors. The discussion includes mechanisms, therapeutic strategies, and clinical prospects of this novel treatment.

Originally published by gnews